Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Zinc finger protein 671
(
ZNF671
) is a member of the largest transcription factor family in the human genome. However, the methylation status, expression, and prognostic role of
ZNF671
in solid tumors remain unclear. The aim of this study was to explore the relationship between
ZNF671
and the prognosis of patients with solid tumors. We performed a pan-cancer analysis of the methylation status and mRNA and protein expression of
ZNF671
using The Cancer Genome Atlas (TCGA) database and the Human Protein Atlas. We further evaluated the prognostic value of
ZNF671
expression among numerous cancer types using the "Kaplan-Meier plotter" (KM plotter) database. We found that downregulation of
ZNF671
is associated with hypermethylation of its promoter. Survival analysis established that the downregulation of
ZNF671
predicts poor prognosis in breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), head and neck squamous cell carcinoma (HNSC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), pancreatic adenocarcinoma (PAAD), and uterine corpus
endometrial carcinoma
(UCEC) solid tumors. CCK-8 and Transwell functional assays showed that
ZNF671
could inhibit tumor cell proliferation, migration, and invasion. These results indicate that
ZNF671
is an excellent predictive factor for BRCA, CESC, HNSC, KIRP, LUAD, PAAD, SARC, and UCEC solid tumors and may play crucial roles in the development and progression of these tumors.
...
PMID:Epigenetic-Mediated Downregulation of Zinc Finger Protein 671 (
ZNF671
) Predicts Poor Prognosis in Multiple Solid Tumors. 3113 49